Therapeutic Antibodies

#Acute inflammatory conditions #Financing #GPCRs #Maxion Therapeutics #Therapeutic Antibodies

Maxion Therapeutics raises $72m to advance KnotBody pipeline

Maxion Therapeutics has raised $72 million in an oversubscribed Series A Financing to advance its antibody-based KnotBody drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases.  The financing was led by General Catalyst with additional investment from new investors, British Patient Capital, Solasta Ventures and… Read More

#Business & Investment #News

B-cells in multiple myeloma
#Acquisition #Bispecific Antibodies #Dren Bio #Finance #Immunology #Sanofi

Bi-specific antibody acquisition broadens immunology pipeline

Sanofi and Dren Bio, a clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific antibody that… Read More

#Business & Investment #News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

Webinar: Therapeutic antibody innovation

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

Webinar highlights innovation in therapeutic antibody discovery

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Monoclonal antibodies
#Antibodies #Biotechnology #Collaboration #Drug development #Drug discovery #Pierre Fabre Laboratories #RedRidge

Pharma/biotech biparatopic antibody collaboration agreed

Pierre Fabre Laboratories and RedRidge have announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody (BPA) drug candidates against multiple targets. In line with Pierre Fabre Laboratories’ innovation strategy, the partnership’s therapeutic focus will be on precision oncology as well as dermatology and rare diseases. Read More

#News

#Antibody drug conjugate (ADC) #Big pharma #Drug development #Drug discovery #Heidelberg Pharma #Takeda #Therapeutic Antibodies

A global overview of therapeutic antibody development

DDW’s Megan Thomas takes a wide-angle look at the sector and speaks to experts and thought leaders about their predictions for therapeutic antibodies in 2025. Clinical advancements Marcelo Freire, Vice President of Global Medical Affairs, Therapeutic Area Head of Gastroenterology at Takeda, comments on monoclonal antibodies (mAbs) from a gastro… Read More

#Business & Investment #Exclusive Content

Bispecific antibodies
#Antibodies #Bispecific Antibodies #Monoclonal antibodies #Therapeutic Antibodies

Download the Article: The discovery and evolution of antibody formats

As antibody therapeutics evolve, new formats such as bispecific antibodies (bsAbs) and Fab fragments offer new and exciting therapeutic opportunities. However, traditional mAb isolation methods are often ineffective, necessitating innovative solutions. This Article explores these challenges and introduces Astrea Bioseparations’ Fabsorbent F1P HF as an alternative strategy for isolating… Read More

#News

Ki67 staining
#Antibody drug conjugate (ADC) #Biospecimen collection #Monoclonal antibodies #Oncology

Advancing cancer therapy with antibody-drug conjugates

Cathie Miller, PhD, Senior Director of Product Marketing at BioIVT, discusses biospecimens and analytical techniques supporting the rapid evolution of ADCs in oncology. Antibody-drug conjugates (ADCs) are making significant strides forward as targeted cancer therapies. By coupling the specificity of antibodies with the potency of cytotoxic drugs, ADCs aim to… Read More

#Cancer Research #Exclusive Content

#Antibodies #Bispecific Antibodies #Monoclonal antibodies #Therapeutic Antibodies

The Discovery and Evolution of Antibody Formats

As antibody therapeutics evolve, new formats such as bispecific antibodies (bsAbs) and Fab fragments offer new and exciting therapeutic opportunities. However, traditional mAb isolation methods are often ineffective, necessitating innovative solutions. This article explores these challenges and introduces Astrea Bioseparations’ Fabsorbent™ F1P HF as an alternative strategy for isolating next-generation… Read More

#Resources

Drugs targeting amyloid Plaque
#Alzheimer's #Drug safety #Eisai #Monoclonal antibodies #National Institute for Health and Care Excellence (NICE)

Researchers call for extra safety monitoring of lecanemab

Researchers from the UK’s Drug Safety Research Unit are calling for the robust monitoring of the safety of lecanemab, a new drug to treat Alzheimer’s disease (AD).  In a review article, published in the British Journal for Clinical Pharmacology, the… Read More

#News #Regulatory #Trending News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

What are the drivers and challenges in therapeutic antibody discovery?

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

#Biologics #Cell line development #Cell lines #Drug discovery #Proteins

Where do we stand with cell line development?

DDW’s Megan Thomas examines the value and impact of cell line development in the drug discovery industry. When it comes to the creation of biologics, cell line development is an essential drug discovery process. From a functional perspective, when it comes to monoclonal antibodies (mAbs), enzymes, or other therapeutic proteins,… Read More

#Exclusive Content

#Antibodies #Monoclonal antibodies #Pandemic prevention #Pandemic response

Polyclonal and recombinant antibody development

Joerg Schuettrumpf, Chief Scientific Innovation Officer at Grifols, discusses advancements in antibody therapies, focusing on IgA, IgM, and recombinant polyclonal technologies to enhance treatment efficacy, scalability, and preparedness for global health challenges. IgA and IgM therapies The therapeutic antibody field is progressing rapidly, says Schuettrumpf, with key advances in broad-spectrum… Read More

#Exclusive Content

#Therapeutic Antibodies

Digital Article: The Discovery and Evolution of Antibody Formats

As antibody therapeutics evolve, new formats such as bispecific antibodies (bsAbs) and Fab fragments offer new and exciting therapeutic opportunities. However, traditional mAb isolation methods are often ineffective, necessitating innovative solutions. This article explores these challenges and introduces Astrea Bioseparations’ Fabsorbent™ F1P HF as an alternative strategy for isolating next-generation… Read More

#Digital Articles

Monoclonal antibodies
#Inflammatory Bowel Disease #Monoclonal antibodies #Phase II trial #Sanofi #Teva

New data indicate duvakitug could “transform” IBD treatment

Sanofi and Teva Pharmaceuticals have revealed new results from their Phase IIb study of duvakitug for ulcerative colitis (UC) and Crohn’s disease (CD), the two most common forms of inflammatory bowel disease (IBD).   The results were shared in two oral presentations at the 20th Congress of the… Read More

#News #Trending News

Monoclonal antibody
#Dermatology #FDA #Monoclonal antibodies #Orphan drugs #Rare disease

Dupixent for bullous pemphigoid under FDA priority review

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).  The sBLA is supported by data from a pivotal study evaluating the efficacy and safety of Dupixent in… Read More

#News #Regulatory